Natalizumab

Drugs of Today

Volumn 42, Issue 10, 2006, Pages 639-655

  Berger, Joseph R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CAMPTOTHECIN; CIDOFOVIR; CLADRIBINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 2; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; SMALL INTERFERING RNA; TOPOTECAN; VASCULAR CELL ADHESION MOLECULE 1;

ANAPHYLAXIS; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; HEADACHE; HERPES; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PATHOGENESIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SKIN ALLERGY; TONSILLITIS; URTICARIA;

ANTIBODIES, MONOCLONAL; HUMANS; INTEGRIN ALPHA4; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS;

EID: 33845452879     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.10.1042190     Document Type: Review

References (139)

1. Davidson, N.J. The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease. Expert Opin Investig Drugs 1998, 7: 1115-20.
2. Moller, B., Villiger, P.M. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006, 27: 391-408.
3. Saxena, N., Aggarwal, A., Misra, R. Elevated concentrations of monocyte-derived cytokines in synovial fluid of children with enthesitis-related arthritis and polyarticular types of juvenile idiopathic arthritis. J Rheumatol 2005, 32: 1349-53.
4. Peloso, P.M., Braun, J. Expanding the armamentarium for the spondyloarthropathies. Arthritis Res Ther 2004, 6 (Suppl. 2): S36-43.
5. Tobin, A.M., Kirby, B. TNF-alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005, 19: 47-57.
6. Lipsky, P.E., van der Heijde, D.M., St Clair, E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343: 1594-602.
7. Gorman, J.D., Sack, K.E., Davis, J.C. Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346: 1349-56.
8. Oh, C.J., Das, K.M., Gottlieb, A.B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000, 42 (5 Pt. 1): 829-30.
9. Rutgeerts, P., Sandborn, W.J., Feagan, B.G. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353: 2462-76.
10. Day, R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002, 359: 540-1.
11. Scheinfeld, N. Adalimumab: A review of side effects. Expert Opin Drug Saf 2005, 4: 637-41.
12. Bongarts, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295: 2275-85.
13. Mohan, N., Edwards, E.T., Cupps, T.R. et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44: 2862-9.
14. Sukal, S.A., Nadiminti, L., Granstein, R.D. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006, 54: 160-4.
15. Butcher, E.C., Picker, L.J. Lymphocyte homing and homeostasis. Science 1996, 272: 60-6.
16. Steinman, L. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov 2005, 4: 510-8.
17. Rudick, R.A., Sandrock, A. Natalizumab: Alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004, 4: 571-80.
18. Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L., Karin, N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356: 63-6.
19. Keszthelyi, E., Karlik, S., Hyduk, S. et al. Evidence for a prolonged role of alpha 4 integrin throughout active experimental allergic encephalomyelitis. Neurology 1996, 47: 1053-9.
20. Tysabri® (natalizumab) prescribing information. Biogen Idec 2004, Cambridge, MA, USA.
21. Bochner, B.S., Luscinskas, F.W., Gimbrone, M.A. Jr. et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: Contributions of endothelial cell adhesion molecules. J Exp Med 1991, 173: 1553-7.
22. Lobb, R.R., Hemler, M.E. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994, 94: 1722-8.
23. Madri, J.A., Graesser, D., Haas, T. The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Biochem Cell Biol 1996, 74: 749-57.
24. Damle, N.K., Aruffo, A. Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+ T lymphocytes. Proc Natl Acad Sci USA 1991, 88: 6403-7.
25. Burkly, L.C., Jakubowski, A., Newman, B.M., Rosa, M.D., Chi-Rosso, G., Lobb, R.R. Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol 1991, 21: 2871-5.
26. Correale, J., Bassani Molinas Mde, L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003, 140: 198-209.
27. Hellings, N., Gelin, G., Medaer, R., Bruckers, L., Palmers, Y., Raus, J., Stinissen, P. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: Association with clinical and MRI activity. J Neuroimmunol 2002, 126: 143-60.
28. Rice, G.P., Hartung, H.P., Calabresi, P.A. Anti-alpha4 integrin therapy for multiple sclerosis: Mechanisms and rationale. Neurology 2005, 64: 1336-42.
29. Hamann, A., Andrew, D.P., Jablonski-Westrich, D., Holzmann, B., Butcher, E.C. Role of alpha 4 integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994, 152: 3282-93.
30. Van Assche, G., Vermeire, S., Rutgeerts, P. Emerging biological treatments in inflammatory bowel diseases. Dig Dis 2006, 24: 131-6.
31. Sandborn, W.J., Colombel, J.F., Enns, R. et al; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353: 1912-25.
32. Danese, S., Semeraro, S., Marini, M. et al. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Dig Liver Dis 2005, 37: 811-8.
33. Ghosh, S., Goldin, E., Gordon, F.H. et al.; Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N Engl J Med 2003, 348: 24-32.
34. Barry, S.T., Ludbrook, S.B., Murrison, E., Morgan, C.M. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res 2000, 258: 342-51.
35. Stuve, O., Marra, C.M., Jerome, K.R. et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol, 2006, 59: 743-7.
36. Tubridy, N., Behan, P.O., Capildeo, R. et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999, 53: 466-72.
37. Compston, A., Confavreux, C. The distribution of multiple sclerosis. In: Compston, A., Confavreux, C., Lassmann, H. et al. (Eds.). McAlpine's Multiple Sclerosis. Churchill Livingstone Elsevier: New York 2005, 71-111.
38. Anderson, D.W., Ellenberg, J.H., Leventhal, C.M., Reingold, S.C., Rodriguez, M., Silberberg, D.H. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992, 31: 333-6.
39. Kobelt, G., Berg, J., Atherly, D., Hadjimichael, O. Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology 2006, 66: 1696-702.
40. Orlewska, E., Mierzejewski, P., Zaborski, J. et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 2005, 12: 31-9.
41. Grima, D.T., Torrance, G.W., Francis, G., Rice, G., Rosner, A.J., Lafortune, L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000, 6: 91-8.
42. Goodin, D.S., Frohman, E.M., Garmany, G.P. Jr. et al.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58: 169-78.
43. Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983, 33: 1444-52.
44. Cutter, G.R., Baier, M.L., Rudick, R.A. et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999, 122 (Pt. 5): 871-82.
45. Munari, L., Lovati, R., Boiko, A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2004: CD004678.
46. Rice, G.P., Incorvaia, B., Munari, L. et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001: CD002002.
47. Jeffery, D.R., Herndon, R. Review of mitoxantrone in the treatment of multiple sclerosis. Neurology 2004, 63 (Suppl. 6): S19-24.
48. Edan, G., Miller, D., Clanet, M. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997, 62: 112-8.
49. Millefiorini, E., Gasperini, C., Pozzilli, C. et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997, 244: 153-9.
50. Martinelli Boneschi, F., Rovaris, M., Capra, R., Comi, G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005: CD002127.
51. Miller, D.H., Khan, O.A., Sheremata, W.A. et al.; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348: 15-23.
52. O'Connor, P.W., Goodman, A., Willmer-Hulme, A.J. et al; Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. Neurology 2004, 62: 2038-43.
53. Vollmer, T.L., Phillips, J.T., Goodman, A.D. et al. An open-label safety and drug interaction study of natalizumab (Antegren®) in combination with interferon-beta (Avonex®) in patients with multiple sclerosis. Mult Scler 2004, 10: 511-20.
54. Dalton, C.M., Miszkiel, K.A., Barker, G.J. et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004, 251: 407-13.
55. Doggrell, S.A. Is natalizumab a breakthrough in the treatment of multiple sclerosis? Expert Opin Pharmacother 2003, 4: 999-1001.
56. Chaudhuri, A., Behan, P.O. Natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348: 1598-9; author reply 1598-9.
57. Miller, D., O'Connor, P. Natalizumab for relapsing multiple sclerosis. New Eng J Med 2003, 348: 1598-9.
58. Polman, C.H., O'Connor, P.W., Havrdova, E. et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354: 899-910.
59. O'Connor, P.W., Goodman, A., Kappos, L. et al. The safety and tolerability of natalizumab: Results from the safety-extension study in patients with multiple sclerosis. Neurology 2006, 66 (Suppl. 2): A34.
60. Rudick, R.A., Stuart, W.H., Calabresi, P.A. et al.; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354: 911-23.
61. Kleinschmidt-Demasters, B.K., Tyler, K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon-beta-1a for multiple sclerosis. N Engl J Med 2005, 353: 369-74.
62. Langer-Gould, A., Atlas, S.W., Green, A.J., Bollen, A.W., Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353: 375-81.
63. Van Assche, G., Van Ranst, M., Sciot, R. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353: 362-8.
64. Ropper, A.H. Selective treatment of multiple sclerosis. N Engl J Med 2006, 354: 965-7.
65. Tenser, R.B. Natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354: 2387-9; author reply 2387-9.
66. Best, W.R., Becktel, J.M., Singleton, J.W., Kern, F. Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70: 439-44.
67. von Andrian, U.H., Engelhardt, B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003, 348: 68-72.
68. Weber, F., Goldmann, C., Kramer, M. et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 2001, 49: 636-42.
69. ZuRhein, G. Particles resembling papovavirions in human cerebral demyelinating disease. Science 1965, 148: 1477-9.
70. Padgett, B.L., Walker, D.L., ZuRhein, G.M., Eckroade, R.J., Dessel, D.H. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1: 1257-60.
71. Major, E.O., Amemiya, K., Tornatore, C.S., Houff, S.A., Berger, J.R. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992, 5: 49-73.
72. Walker, D., Padgett, B. The epidemiology of human polyomaviruses. In: Sever, J., Madden, D. (Eds.). Polyomaviruses and human neurological disease. Alan R. Liss, Inc.: New York 1983, 99-106.
73. Brown, P., Tsai, T., Gajdusek, D.C. Seroepidemiology of human papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am J Epidemiol 1975, 102: 331-40.
74. Caldarelli-Stefano, R., Vago, L., Omodeo-Zorini, E. et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neurovirol 1999, 5: 125-33.
75. Monaco, M.C., Atwood, W.J., Gravell, M., Tornatore, C.S., Major, E.O. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: Implications for viral latency. J Virol 1996, 70: 7004-12.
76. Sabath, B.F., Major, E.O. Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J Infect Dis 2002, 186 (Suppl. 2): S180-6.
77. Monaco, M.C., Jensen, P.N., Hou, J., Durham, L.C., Major, E.O. Detection of JC virus DNA in human tonsil tissue: Evidence for site of initial viral infection. J Virol 1998, 72: 9918-23.
78. Elphick, G.F., Querbes, W., Jordan, J.A. et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004, 306: 1380-3.
79. Pho, M.T., Ashok, A., Atwood, W.J. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 2000, 74: 2288-92.
80. Querbes, W., Benmerah, A., Tosoni, D., Di Fiore, P.P., Atwood, W.J. A JC virus-induced signal is required for infection of glial cells by a clathrin- and eps15-dependent pathway. J Virol 2004, 78: 250-6.
81. Berger, J., Major, E. Progressive multifocal leukoencephalopathy. In: Merigan, T.J., Bartlett, J., Bolognesi, D. (Eds.). Textbook of AIDS Medicine. Williams & Wilkins: Baltimore 1999, 403-20.
82. Watanabe, I., Preskorn, S.H. Virus-cell interaction in oligodendroglia, astroglia and phagocyte in progressive multifocal leukoencephalopathy. An electron microscopic study. Acta Neuropathol (Berl) 1976, 36: 101-15.
83. Mazlo, M., Tariska, I. Are astrocytes infected in progressive multifocal leukoencephalopathy (PML)? Acta Neuropathol 1982, 56: 45-51.
84. Tornatore, C., Berger, J.R., Houff, S.A. et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992, 31: 454-62.
85. Andreoletti, L., Lescieux, A., Lambert, V. Semi-quantitative detection of JCV DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy. J Med Virol 2002, 66: 1-7.
86. Berger, J.R., Koralnik, I.J. Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences. N Engl J Med 2005, 353: 414-6.
87. Koralnik, I.J., Boden, D., Mai, V.X., Lord, C.I., Letvin, N.L. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999, 52: 253-60.
88. Berger, U.R., Miller, C.S., Mootoor, Y., Avdiushko, S.A., Kryscio, R.J., Zhu, H. JC virus detection in bodily fluids: Clues to transmission. Clin Infect Dis 2006, 43: e9-12.
89. Weber, T., Weber, F., Petry, H., Luke, W. Immune response in progressive multifocal leukoencephalopathy: An overview. J Neurovirol 2001, 7: 311-7.
90. Du Pasquier, R.A., Corey, S., Margolin, D.H. et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003, 61: 775-82.
91. Astrom, K.E., Mancall, E.L., Richardson, E.P. Jr. Progressive multifocal leukoencephalopathy: A hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958, 81: 93-111.
92. Brooks, B.R., Walker, D.L. Progressive multifocal leukoencephalopathy. Neurol Clin 1984, 2: 299-313.
93. Bernick, C., Gregorios, J.B. Progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome. Arch Neurol 1984, 41: 780-2.
94. Miller, J.R., Barrett, R.E., Britton, C.B. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982, 307: 1436-8.
95. Snider, W.D., Simpson, D.M., Nielsen, S., Gold, J.W., Metroka, C.E., Posner, J.B. Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients. Ann Neurol 1983, 14: 403-18.
96. Berger, J.R., Kaszovitz, B., Post, M.J., Dickinson, G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987, 107: 78-87.
97. Kure, K., Llena, J.F., Lyman, W.D. et al. Human immunodeficiency virus-1 infection of the nervous system: An autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol 1991, 22: 700-10.
98. Selik, R.M., Karon, J.M., Ward, J.W. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997, 176: 632-6.
99. Yousry, T.A., Major, E.O., Ryschkewitsch, C. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354: 924-33.
100. Berger, J.R., Levy, R.M., Flomenhoft, D., Dobbs, M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998, 44: 341-9.
101. Henin, D., Smith, T.W., De Girolami, U., Sughayer, M., Hauw, J.J. Neuropathology of the spinal cord in the acquired immunodeficiency syndrome. Hum Pathol 1992, 23: 1106-14.
102. Whiteman, M.L., Post, M.J., Berger, J.R., Tate, L.G., Bell, M.D., Limonte, L.P. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: Neuroimaging with clinical and pathologic correlation. Radiology 1993, 187: 233-40.
103. Safdar, A., Rubocki, R.J., Horvath, J.A., Narayan, K.K., Waldron, R.L. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: Impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002, 35: 1250-7.
104. Vendrely, A., Bienvenu, B., Gasnault, J., Theibault, J.B., Salmon, D., Gray, F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl) 2005, 109: 449-55.
105. Moret, H., Brodard, V., Barranger, C., Jovenin, N., Joannes, M., Andreoletti, L. New commercially available PCR and microplate hybridization assay for detection and differentiation of human polyomaviruses JC and BK in cerebrospinal fluid, serum, and urine samples. J Clin Microbiol 2006, 44: 1305-9.
106. Weber, T., Klapper, P.E., Cleator, G.M. et al. Polymerase chain reaction for detection of JC virus DNA in cerebrospinal fluid: A quality control study. European Union Concerted Action on Viral Meningitis and Encephalitis. J Virol Methods 1997, 69: 231-7.
107. Du Pasquier, R.A., Clark, K.W., Smith, P.S. et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol 2001, 7: 318-22.
108. Koralnik, I.J. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 2002, 8 (Suppl. 2): 59-65.
109. Koralnik, I.J., Du Pasquier, R.A., Letvin, N.L. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001, 75: 3483-7.
110. De Luca, A., Giancola, M.L., Ammassari, A. et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 2000, 182: 1077-83.
111. Du Pasquier, R.A., Koralnik, I.J. Inflammatory reaction in progressive multifocal leukoencephalopathy: Harmful or beneficial? J Neurovirol 2003, 9 (Suppl. 1): 25-31.
112. Hoffmann, C., Horst, H.A., Albrecht, H., Schlote, W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003, 74: 1142-4.
113. Cinque, P., Bossolasco, S., Brambilla, A.M. et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: Study of 43 cases with review of the literature. J Neurovirol 2003, 9 (Suppl. 1): 73-80.
114. Cinque, P., Pierotti, C., Vigano, M.G. et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001, 7: 358-63.
115. Thurnher, M.M., Post, M.J., Rieger, A., Kleibl-Popov, C., Loewe, C., Schindler, E. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR 2001, 22: 977-84.
116. Di Giambenedetto, S., Vago, G., Pompucci, A. et al. Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: A new clinical entity? Neurology 2004, 63: 2452-3.
117. Goodman, A., Goodman, L., Rail, T. et al. The Pharmacological Basis of Therapeutics. MacMillan Publishing Co.: New York 1985.
118. Hou, J., Major, E.O. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998, 4: 451-6.
119. Bauer, W.R., Turel, A.P. Jr., Johnson, K.P. Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA 1973, 226: 174-6.
120. Conomy, J., Beard, N., Matsumoto, H. et al. Cytarabine treatment of progressive multifocal leukoencephalopathy. JAMA 1974, 229: 1313-6.
121. Lidman, C., Lindqvist, L., Mathiesen, T., Grane, P. Progressive multifocal leukoencephalopathy in AIDS. AIDS 1991, 5: 1039-41.
122. O'Riordan, T., Daly, P., Hutchinson, M. et al. Progressive multifocal leukoencephalopathy - Remission with cytarabine. J Infect Dis 1990, 20: 51-4.
123. Tashiro, K., Doi, S., Moriwaka, F., Maruo, Y., Nomura, M. Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon. J Neurol 1987, 234: 427-9.
124. Van Horn, G., Bastian, F., Moake, J. Progressive multifocal leukoencephalopathy: Failure of response to transfer factor and cytarabine. Neurology 1978, 28: 794-7.
125. Hall, C.D., Dafni, U., Simpson, D. et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998, 338: 1345-51.
126. Chang, L., Ernst, T., Tornatore, C. et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997, 48: 836-45.
127. Kerr, D.A., Chang, C.F., Gordon, J., Bjornisti, M.A., Khalili, K. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 1993, 196: 612-8.
128. O'Reilly, S. Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet 1997, 350: 291.
129. Andrei, G., Snoeck, R., Vandeputte, M., De Clercq, E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997, 41: 587-93.
130. Marra, C.M., Rajicic, N., Barrer, D.E. et al.; Adult AIDS Clinical Trials Group 363 Team. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002, 16: 1791-7.
131. Radhakrishnan, S., Gordon, J., Del Valle, L., Cui, J., Khalili, K. Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. J Virol 2004. 78: 7264-9.
132. Kunschner, L., Scott, T.F. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 2005, 65: 1510.
133. Przepiorka, D., Jaeckle, K.A., Birdwell, R.R. et al. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant 1997, 20: 983-7.
134. Steiger, M.J., Tarnesby, G., Gabe, S., McLaughlin, J., Schapira, A.M. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 1993, 33:407-11.
135. Huang, S.S., Skolasky, R.L., Dal Pan, G.J., Royal, W. 3rd, McArthur, J.C. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: An observational study. J Neurovirol 1998, 4: 324-32.
136. Major, E., Ryschkewitsch, C., Fahle, G. et al. Lao evaluation of JCV DNA in DNA and plasma in Tysabri® patients. Presented at the ECTRIMS meeting, Thessaloniki, 2005.
137. U.S. Food and Drug Administration's Web page on natalizumab (Tysabri®) information, accessed Sept 5,2006: http://www.fda.gov/cder/drug/ infopage/natalizumab/
138. European Agency for the Evaluation of Medicinal Products, European Public Assessment Report (EPAR), Tysabri®, EPAR summary for the public, accessed Sept. 5, 2006: http://www. emea.eu.int/humandocs/PDFs/EPAR/tysabri/ TysabriEPARsummary-en.pdf
139. Polman, C.H., Reingold, S.C., Edan, G. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58: 840-6.